Prescription drug · NDA
Vumerity (diroximel fumarate) NDC 64406-020
Diroximel fumarate 231 mg/1 · Capsule · Oral · Biogen Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 64406-020-03 | 64406002003 | 1 BOTTLE, PLASTIC in 1 CARTON (64406-020-03) / 120 CAPSULE in 1 BOTTLE, PLASTICMarketed from Oct 29, 2019 | |
| 64406-020-07 | 64406002007 | 1 BOTTLE, PLASTIC in 1 CARTON (64406-020-07) / 14 CAPSULE in 1 BOTTLE, PLASTICMarketed from Sep 1, 2022 · Sample package |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Vumerity
- Generic name (nonproprietary)
- diroximel fumarate
- Active ingredients
- Diroximel fumarate — 231 mg/1
- Dosage form
- Capsule
- Route
- Oral
- Labeler
- Biogen Inc.
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 211855
- Marketing start
- Listing expires
- Identifiers
- Product ID 64406-020_25e0bcfe-8df7-4a62-9db1-ba39a266e8bdSPL ID 25e0bcfe-8df7-4a62-9db1-ba39a266e8bdSPL set ID 2d74414f-6b83-4ea2-9a95-3cecabbce774RxCUI 2261788, 2261794UNII K0N0Z40J3WUPC 0364406020032
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N464406002003followed by a unit qualifier and the quantityPackage 64406-0020-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
VUMERITY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. VUMERITY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )
Excerpt only. Read the full label for complete information.